Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation

Drug Category: Array
Conference Category: Array
Lead Author: Mato A, et al.
Published Date: 02/12/2018
Download Link: /wp-content/uploads/2019/03/ASH-2018-U2-Pembro-Mato-Final.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top